


COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
 (Currently amended claims showing deletions by ~~striketrough~~
 and additions by underlining)

1 (currently amended): A compound of formula I,



wherein

n_1 is \emptyset 1;


X is, independently for each occurrence, $(\text{CHR}^{11})_{n_3}(\text{CH}_2)_{n_4}\text{Z}(\text{CH}_2)_{n_5}$;

Z is O, $\text{N}(\text{R}^{12})$, S, or a bond;

n_3 is, independently for each occurrence, 0 or 1;

n_4 and n_5 each is, independently for each occurrence, 0, 1, 2, or 3;

Y is, independently for each occurrence, CO, CH_2 , CS, or a bond;



R^2 , R^{11} , and R^{12} each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl and

aryl, wherein said optionally substituted moiety is optionally substituted with one or more of R^8 or R^{30} ; R^3 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{2-6}) alkynyl, (C_{3-6}) cycloalkyl, (C_{3-6}) cycloalkyl (C_{1-6}) alkyl, (C_{5-7}) cycloalkenyl, (C_{5-7}) cycloalkenyl (C_{1-6}) alkyl, aryl, aryl (C_{1-6}) alkyl, heterocyclyl, and heterocyclyl (C_{1-6}) alkyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} ;

R^4 and R^5 each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{3-6}) cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} , wherein each said substituent is independently selected, or R^4 and R^5 can be taken together with the carbons to which they are attached to form aryl;

R^6 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{3-6}) cycloalkyl, (C_{3-6}) cycloalkyl (C_{1-6}) alkyl, (C_{5-7}) cycloalkenyl, (C_{5-7}) cycloalkenyl (C_{1-6}) alkyl, aryl, aryl (C_{1-6}) alkyl, heterocyclyl, and heterocyclyl (C_{1-6}) alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C_{1-6}) alkyl, (C_{1-6}) alkoxy, $-N(R^8R^9)$, $-COOH$, $-CON(R^8R^9)$, and halo, where R^8 and R^9 each is, independently for each occurrence, H, (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{2-6}) alkynyl, aryl, or aryl (C_{1-6}) alkyl;


R^7 is, independently for each occurrence, H, =O, =S, or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{3-6}) cycloalkyl,

(C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, -N(R⁸R⁹), -COOH, -CON(R⁸R⁹), and halo;

R¹⁰ is C;

R²¹ is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and aryl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of R⁸ and R³⁰;

R²² is H, (C₁₋₆)alkylthio, (C₃₋₆)cycloalkylthio, R⁸-CO-, or a substituent according to the formula



R²⁴ and R²⁵ each is, independently for each occurrence, H, (C₁₋₆)alkyl, or aryl(C₁₋₆)alkyl;

R³⁰ is, independently for each occurrence, (C₁₋₆)alkyl, -O-R⁸, -S(O)_{n6}R⁸, -S(O)_{n7}N(R⁸R⁹), -N(R⁸R⁹), -CN, -NO₂,


$-\text{CO}_2\text{R}^8$, $-\text{CON}(\text{R}^8\text{R}^9)$, $-\text{NCO}-\text{R}^8$, or halogen;

n_6 and n_7 each is, independently for each occurrence, 0, 1, or 2;


wherein said heterocyclyl is azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, or thienyl; and wherein said aryl is phenyl or naphthyl;

provided that:

either R^6 is H or R^7 is $=\text{O}$, $-\text{H}$, or $=\text{S}$ wherein when R^6 is H,




then R^{10} and R^7 are taken together to form (R^{10}) ; or when R^7 is $=\text{O}$, $-\text{H}$, or $=\text{S}$, then R^{10} and R^6 are taken together




to form

wherein X^1 , X^2 , and X^3 each is, independently, H, halogen, $-\text{NO}_2$, $-\text{NCO}-\text{R}^8$, $-\text{CO}_2\text{R}^8$, $-\text{CN}$, or $-\text{CON}(\text{R}^8\text{R}^9)$; and when R^1 is $\text{N}(\text{R}^{24}\text{R}^{25})$, then n_3 is 1, n_4 and n_5 each is 0, Z is a bond, and R^3 and R^{11} can be taken together to form




wherein n_2 is 1-6, and X^4 and X^5 each is, independently, H, (C_{1-6}) alkyl, or aryl, or X^4 and X^5 can be taken together to form (C_{3-6}) cycloalkyl; or a pharmaceutically acceptable salt thereof.

2 (original): A compound according to claim 1, wherein:




3 (withdrawn): A compound according to claim 2, wherein:



or a pharmaceutically acceptable salt thereof.

4 (withdrawn): A compound according to claim 2, wherein:



R¹ is R²²-S ;

n₃, n₄, and n₅ each is 0;


Z is a bond;

Y is, independently for each occurrence, CO or CS; and

n₁ is 0;

or a pharmaceutically acceptable salt thereof.


5 (original): A compound according to claim 2, wherein:



R¹ is ;

R⁶ is H;

n₁ is 1;



R⁷ and R¹⁰ are taken together to form

n₃ is 1 and R¹¹ is H;

Z is O or a bond;

n₅ is 0; and

Y is CO, CH₂, or a bond;

or a pharmaceutically acceptable salt thereof.

6 (withdrawn): A compound according to claim 2,
 wherein:

R^1 is $N(R^{24}R^{25})$;

n_1 is 0;


n_3 is 1;

n_4 is 0;

n_5 is 0;


Y is CO or CS;

Z is a bond; and



R^3 and R^{11} are taken together to form
 or a pharmaceutically acceptable salt thereof.


7 (original): A compound according to claim 2,
 wherein:



R^1 is ;

R^7 is H or =O;

n_1 is 1;



R^6 and R^{10} are taken together to form

n_3 is 1 and R^{11} is H;

n_5 is 0;

Y is CO or CH_2 ; and

Z is O or a bond;

or a pharmaceutically acceptable salt thereof.

8 (withdrawn): A compound according to claim 3, wherein said compound is

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or

2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or a pharmaceutically acceptable salt thereof.

9 (previously presented): A compound according to claim 5, wherein said compound is

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.

10 (previously presented): A compound according to claim 9, wherein said compound is

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.

11 (withdrawn): A compound according to claim 6, wherein said compound is

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;

or a pharmaceutically acceptable salt thereof.

12 (original): A compound according to claim 7,
wherein said compound is

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-
ethyl)-5,6-dihydro-2-phenyl-1H-imidazo[1,2-
a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.


13 (original): A compound according to claim 2
wherein said compound is







1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-
methoxyphenyl) imidazo[1,2a][1,4]benzodiazepine;







1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-
oxoethyl) imidazo[1,2a][1,4]benzodiazepine; or






1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-
oxoethyl) imidazo[1,2a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.







14 (currently amended): A compound according to
claim 2, wherein said compound is


















or a pharmaceutically acceptable salt thereof.

15 (previously presented): A pharmaceutical composition for use in treating a disease selected from the group consisting of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer,

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 18


epidermal cancer and hematopoietic cancer, comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.






16 (previously presented): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer and hematopoietic cancer.





17 (canceled)

18 (canceled)

19 (original): A compound according to claim 2, wherein said compound is







or a pharmaceutically acceptable salt thereof.

20 (previously presented): A pharmaceutical composition for use in treating a disease selected from the group consisting of fibrosis, benign prostatic hyperplasia,

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 21

atherosclerosis, restenosis and hepatitis delta virus infection comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

21 (previously presented): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis and hepatitis delta virus infection.